Could neoadjuvant chemotherapy increase postoperative complication risk of laparoscopic total gastrectomy? A mono-institutional propensity score-matched study in China

Table 5 Clinical characteristics and surgical indicators in pTNM III patients between laparoscopic total gastrectomy after neoadjuvant chemotherapy and laparoscopic total gastrectomy group

Variable	NC-LTG group (n = 34)	LTG group (n = 33)	P value
Sex			0.324
Male	29	25
Female	5	8
Age (yr, mean ± SD)	59.56 ± 9.84	58.18 ± 12.85	0.623
BMI (kg/m2, mean ± SD)	23.24 ± 2.85	24.09 ± 3.20	0.250
ASA grade			0.160
I	3	1
II	30	29
III	1	3
Surgical time, min (mean ± SD)	237.44 ± 46.86	228.03 ± 39.39	0.378
Blood loss, mL (median, IQR)	200 (100-500)	100 (100-200)	0.078
Retrieved lymph nodes, n (mean ± SD)	32.09 ± 12.32	31.58 ± 11.04	0.858
Fist flatus day, d [median, (IQR)]	4.0 (3.0-5.0)	4.0 (3.0-5.0)	0.844
R0 resection rate, n (%)	1 (2.9)	3 (9.1)	0.288
Postoperative day, d [median, (IQR)]	9.5 (7.0-11.0)	8.0 (7.0-9.5)	0.321
Total complication rate, n (%)	6 (17.6)	6 (18.2)	0.954
Severe complication rate, n (%)	2 (5.9)	3 (9.1)	0.617

NC-LTG: Laparoscopic total gastrectomy after neoadjuvant chemotherapy; LTG: Laparoscopic total gastrectomy; BMI: Body mass index; ASA: American Society of Anesthesiologists; IQR: Interquartile range.